ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, 2 arm, open label, phase II study. It is designed to
compare the efficacy and safety of abemaciclib combined with ET (letrozole or fulvestrant)
versus a short course with induction chemotherapy with paclitaxel followed by maintenance
therapy with abemaciclib combined with ET (letrozole or fulvestrant) in patients with
previously untreated, unresectable locally advanced, or metastatic HR positive/HER2 negative
breast cancer with aggressive disease criteria.